Presentation of lipid antigens by CD1 glycoproteins

Current Pharmaceutical Design

Volumn 15, Issue 28, 2009, Pages 3311-3317

  Schiefner, André ^a   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA C GALACTOSYLCERAMIDE; ALPHA GALACTOSYLCERAMIDE; CD1 ANTIGEN; CD1B ANTIGEN; CD1C ANTIGEN; CD1D ANTIGEN; GALACTOSYLCERAMIDE; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 4; NATURAL KILLER CELL RECEPTOR; T6 ANTIGEN; THREITOLCERAMIDE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN EXPRESSION; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; LIGAND BINDING; MALARIA; MELANOMA; MULTIPLE SCLEROSIS; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS; ANTIGENS, CD1; GLYCOPROTEINS; HUMANS; LIPIDS;

EID: 70449408781     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789105108     Document Type: Review

References (65)

1. Calabi F, Milstein C. A novel family of human major histocompatibility complex-related genes not mapping to chromosome 6. Nature 1986; 323: 540-543 (Pubitemid 16025377)
2. - T lymphocytes to a microbial antigen. Nature 1992; 360: 593-597
3. + T cells. Nature 1994; 372: 691-694
4. Barral DC, Brenner MB. CD1 antigen presentation: How it works. Nat Rev Immunol 2007; 7: 929-941
5. Moody DB, Porcelli SA. Intracellular pathways of CD1 antigen presentation. Nat Rev Immunol 2003; 3: 11-22.
6. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004; 22: 817-890 (Pubitemid 38680443)
7. Van Rhijn I, Koets AP, Im JS, Piebes D, Reddington F, Besra GS, et al. The bovine CD1 family contains Group 1 CD1 proteins, but no functional CD1d. J Immunol 2006; 176: 4888-4893
8. Miller MM, Wang C, Parisini E, Coletta RD, Goto RM, Lee SY, et al. Characterization of two avian MHC-like genes reveals an ancient origin of the CD1 family. Proc Natl Acad Sci USA 2005; 102: 8674-8679 (Pubitemid 40862794)
9. Zeng Z-H, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 1997; 277: 339-345
10. Zajonc DM, Elsliger MA, Teyton L, Wilson IA. Crystal structure of CD1a in complex with sulfatide self antigen at a resolution of 2.15 Å. Nat Immunol 2002; 4: 809-815 (Pubitemid 36986766)
11. Zajonc DM, Crispin MDM, Bowden TA, Young DC, Cheng T-Y, Hu J, et al. Molecular mechanism of lipopeptide presentation by CD1a. Immunity 2005; 22: 209-219 (Pubitemid 40255712)
12. Gadola SD, Zaccai NR, Harlos K, Shepherd D, Castro-Palomino JC, Ritter G, et al. Structure of human CD1b with bound ligands at 2.3 Å, a maze for alkyl chains. Nat Immunol 2002; 3: 721-726 (Pubitemid 34884827)
13. Batuwangala T, Shepherd D, Gadola SD, Gibson KJC, Zaccai NR, Fersht AR, et al. The crystal structure of human CD1b with bound bacterial glycolipid. J Immunol 2004; 172: 2382-2388 (Pubitemid 38182387)
14. Garcia-Alles LF, Versluis K, Maveyraud L, Vallina AT, Sansano S, Bello NF, et al. Endogenous phosphatidylcholine and a long spacer ligand stabilize the lipid-binding groove of CD1b. EMBO J 2006; 25: 3684-3692 (Pubitemid 44264878)
15. Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, Ritter G, et al. The crystal structure of human CD1d with and without α-galactosylceramide. Nat Immunol 2005; 6: 819-826 (Pubitemid 43090468)
16. Borg NA, Wun KS, Kjer-Nielsen L, Wilce MCJ, Pellicci DG, Koh R, et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007; 448: 44-49 (Pubitemid 47037002)
17. Zajonc DM, Cantu C, Mattner J, Zhou D, Savage PB, Bendelac A, et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol 2005; 6: 810-818 (Pubitemid 43090467)
18. Giabbai B, Sidobre S, Crispin MDM, Sanchez Ruiz Y, Bachi A, Kronenberg M, et al. Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine. J Immunol 2005; 175: 977-984
19. Zajonc DM, Maricic I, Wu D, Halder R, Roy K, Wong C-H, et al. Structural basis for CD1d presentation of sulfatide derived myelin and its implications for autoimmunity. J Exp Med 2005; 202: 1517-1526 (Pubitemid 41746598)
20. Wu D, Zajonc DM, Fujio M, Sullivan BA, Kinjo Y, Kronenberg M, et al. Design of natural killer T cell activators: Structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc Natl Acad Sci USA 2006; 103: 3972-3977
21. Zajonc DM, Ainge GD, Painter GF, Severn WB, Wilson IA. Structural characterization of mycobacterial phosphatidylinositol mannoside binding to mouse CD1d. J Immunol 2006; 177: 4577-4583
22. Zajonc DM, Savage PB, Bendelac A, Wilson IA, Teyton L. Crystal structures of mouse CD1d-iGb3 complex and its cognate Vα14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J Mol Biol 2008; 377: 1104-1116
23. Zajonc DM, Striegl H, Dascher CC, Wilson IA. The crystal structure of avian CD1 reveals a smaller, more primordial antigen-binding pocket compared to mammalian CD1. Proc Natl Acad Sci USA 2008; 105: 17925-17930
24. Moody DB, Zajonc DM, Wilson IA. Anatomy of CD1-lipid antigen complexes. Nat Rev Immunol 2005; 5: 387-399
25. De Libero G, Mori L. Recognition of lipid antigens by T cells. Nat Rev Immunol 2005; 5: 485-496
26. Shamshiev A, Gober HJ, Donda A, Mazorra Z, Mori L, De Libero G. Presentation of the same glycolipid by different CD1 molecules. J Exp Med 2002; 195: 1013-1021 (Pubitemid 34412003)
27. Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000; 12: 211-221 (Pubitemid 30398635)
28. Moody DB, Young DC, Cheng TY, Rosat JP, Roura-mir C, O'Connor PB, et al. T cell activation by lipopeptide antigens. Science 2004; 303: 527-531
29. Moody DB, Reinhold BB, Guy MR, Beckman EM, Frederique DE, Furlong ST, et al. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. Science 1997; 278: 283-286
30. Moody DB, Briken V, Cheng TY, Roura-Mir C, Guy MR, Geho DH, et al. Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat Immunol 2002; 3: 435-442 (Pubitemid 34520792)
31. Grant EP, Degano M, Rosat JP, Stenger S, Modlin RL, Wilson IA, et al. Molecular recognition of lipid antigens by T cell receptors. J Exp Med 1999; 189: 195-205. (Pubitemid 29047039)
32. Godfrey, DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114: 1379-1388 (Pubitemid 40385565)
33. Bendelac, A., Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25: 297-336.
34. Berkers, CR, Ovaa H. 2005. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci 2005; 26: 252-257 (Pubitemid 40603073)
35. Van Kaer L. α-Galactosylceramide therapy for autoimmune diseases: Prospects and obstacles. Nat Rev Immunol 2005; 5: 31-42. (Pubitemid 40070329)
36. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C, Zhou D, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434: 525-529 (Pubitemid 40477062)
37. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, Ho DD, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005; 434: 520-525 (Pubitemid 40477061)
38. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia MR, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 2006; 7: 978-986 (Pubitemid 44263912)
39. Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Maillet S, et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci USA 2004; 101: 10685-10690 (Pubitemid 38955803)
40. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997; 278: 1626-1629 (Pubitemid 27516282)
41. Gadola SD, Koch M, Marles-Wright J, Lissin NM, Shepherd D, Matulis G, et al. Structure and binding kinetics of three human CD1d-α- galactosylceramide-specific T cell receptors. J Exp Med 2006; 203: 699-710.
42. Kjer-Nielsen L, Borg NA, Pellicci DG, Beddoe T, Kostenko L, Clements CS, et al. A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1dglycolipid recognition. J Exp Med 2006; 203: 661-673
43. Sullivan BA, Kronenberg M. Activation or anergy: NKT cells are stunned by α-galactosylceramide. J Clin Invest 2005; 115: 2328-2329 (Pubitemid 41266194)
44. Prigozy TI, Naidenko O, Qasba P, Elewaut D, Brossay L, Khurana A, et al. Glycolipid antigen processing for presentation by CD1d molecules. Science 2001; 291: 664-667 (Pubitemid 32150427)
45. Wu D, Xing G-W, Poles MA, Horowitz A, Kinjo Y, Sullivan B, et al. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci USA 2005; 102: 1351-1356 (Pubitemid 40209173)
46. Xing GW, Wu D, Poles MA, Horowitz A, Tsuji M, Ho DD, et al. Synthesis and human NKT cell stimulating properties of 3-O-sulfo-alpha/beta galactosylceramides. Bioorg Med Chem 2005; 13: 2907-2916 (Pubitemid 40387499)
47. Liu Y, Goff RD, Zhou D, Mattner J, Sullivan B, Khurana A, et al. A modified α-galactosyl ceramide for staining and stimulating natural killer T cells. J Immunol Methods 2006; 312: 34-39 (Pubitemid 43795980)
48. Silk JD, Salio M, Reddy BG, Shepherd D, Gileadi U, Brown J, et al. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J Immunol 2008; 180: 6452-6456
49. Morita M, Motoki K, Akimoto K, Natori T, Sakai T, Sawa E, et al. Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J Med Chem 1995; 38: 2176-2187
50. Sidobre S, Hammond KJL, Benazet-Sidobre L, Maltsev SD, Richardson SK, Ndonye RM, et al. The T cell antigen receptor expressed by Vα14i NKT cells has a unique mode of glycosphingolipid antigen recognition. Proc Natl Acad Sci USA 2004; 101: 12254-12259 (Pubitemid 39145430)
51. Lee T, Cho M, Ko SY, Youn HJ, Baek DJ, Cho WJ, et al. Synthesis and evalutation of 1,2,3-triazole containing analogues of the immunostimulant α-GalCer. J Med Chem 2007; 50: 585-589
52. Goff RD, Gao Y, Mattner J, Zhou D, Yin N, Cantu III C, et al. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004; 126: 13602-13603 (Pubitemid 39407224)
53. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells. Nature 2001; 413: 531-534 (Pubitemid 32938752)
54. McCarthy C, Shepherd D, Fleire S, Stronge VS, Koch M, Illarionov PA, et al. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med 2007; 204: 1131-1144 (Pubitemid 46798156)
55. Yu KOA, Im JS, Molano A, Dutronc Y, Illarionov A, Forestier C, et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc Natl Acad Sci USA 2005; 102: 3383-3388 (Pubitemid 40328054)
56. Yang G, Schmieg J, Tsuji M, Franck RW. The C-glycoside analogue of the immunostimulant α-galactosylceramide (KRN7000): synthesis and striking enhancement of activity. Angew Chem Int Ed Engl 2004; 43: 3818-3822 (Pubitemid 39257501)
57. Schmieg J, Yang G, Franck RW, Van Rooijen N, Tsuji M. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci USA 2005; 102: 1127-1132 (Pubitemid 40170737)
58. Fujio M, Wu D, Garcia-Navarro R, Ho DD, Tsuji M, Wong CH. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc 2006; 128: 9022-9023 (Pubitemid 44078971)
59. Chang YJ, Huang JR, Tsai YC, Hung JT, Wu D, Fujio M, et al. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci USA 2007; 104: 10299-10304 (Pubitemid 47185659)
60. Liang PH, Imamura M, Li X, Wu D, Fujio M, Guy RT, et al. Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. J Am Chem Soc 2008; 130: 12348-12354
61. Moody DB, Ulrichs T, Mühlecker W, Young DC, Gurcha SS, Grant E, et al. CD1c-mediated T cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infections. Nature 2000; 404: 884-888
62. Van Rhijn I, Young DC, Im JS, Levery SB, Illarionov PA, Besra GS, et al. CD1d-restricted T cell activation by nonlipidic small molecules. Proc Natl Acad Sci USA 2004; 101: 13578-13583 (Pubitemid 39238445)
63. Heino J, Kapyla J. Cellular receptors of extracellular matrix molecules. Curr Pharm Des 2009; 15(12): 1309-1317
64. Huston SA, Hawkins D. Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention. Curr Pharm Des 2008; 14(12): 1197-1204 (Pubitemid 351997832)
65. Robertson JH, Iga AM, Sales KM, Winslet MC, Seifalian AM. Integrins: a method of early intervention in the treatment of colorectal liver metastases. Curr Pharm Des 2008; 14(3): 296-305.